UBS O'Connor’s Avadel Pharmaceuticals AVDL Stock Holding History

UBS O'Connor’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-40,000	Closed	-$536K	–	443
2014 Q1	$536K	Buy	+40,000	New	+$429K	0.01%	354

Other funds holding AVDL

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCP

Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

UBS O'Connor's AVDL Position: Q2 2014 in Review

UBS O'Connor sold out of Avadel Pharmaceuticals (AVDL) in Q2 2014, closing a stake of 40,000 shares — an estimated $536K sold.

UBS O'Connor first reported a position in AVDL in Q1 2014 and held it in 1 quarter. The position peaked at $536K in Q1 2014. 64 funds tracked by Wall St. Rank hold AVDL as of Q2 2014.

UBS O'Connor reported no remaining Avadel Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
UBS O'Connor sold 40,000 Avadel Pharmaceuticals shares in Q2 2014, an estimated $536K.
UBS O'Connor first reported a position in Avadel Pharmaceuticals in Q1 2014 and held it in 1 quarter.
UBS O'Connor's Avadel Pharmaceuticals position peaked at $536K in Q1 2014.
64 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2014.

Based on UBS O'Connor's 13F filing for Q2 2014, filed 15 Aug 2014.